Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-101 in Short Bowel Syndrome
NCT02242656Phase 3Withdrawn
- Sponsor
- Marathon Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Dec 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of opium tincture in short bowel syndrome (SBS) (2 arms), sponsored by Marathon Pharmaceuticals. Primary endpoint: Percentage of responders between Treatments A and B. Planned start Dec 2014; status: withdrawn.
02
Drugs
opium tincture
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT02242656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242656.